GSK plc — 13F Holdings & Portfolio
CIK 1131399 · latest 13F-HR filed 2026-08-13
GSK plc manages $602.2M in 13F-reported U.S. long-equity assets across 13 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CRSP (29.17%), WVE (17.60%), VIR (14.47%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 0 new positions and exited 0; 6 existing positions rose in reported value and 6 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-13
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- CRISPR THERAPEUTICS AG$22.4M +14.7%
- VIR BIOTECHNOLOGY INC$10.5M +13.7%
- CYTOKINETICS INC$6.6M +29.3%
- IDEAYA BIOSCIENCES INC$5.3M +11.9%
- NKARTA INC$2.3M +34.1%
Top Trims
- WAVE LIFE SCIENCES LTD-$26.3M -19.9%
- LYELL IMMUNOPHARMA INC-$9.1M -30.0%
- FULCRUM THERAPEUTICS INC-$7.2M -52.3%
- CVRX INC-$4.4M -45.7%
- SPERO THERAPEUTICS INC-$1.2M -5.6%
GSK plc Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CRISPR THERAPEUTICS AG | CRSP | H17182108 | $175.7M | 29.17% | 3,220,627 | SH |
| 2 | WAVE LIFE SCIENCES LTD | WVE | Y95308105 | $106.0M | 17.60% | 18,245,691 | SH |
| 3 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $87.1M | 14.47% | 8,550,954 | SH |
| 4 | BIONTECH SE | BNTX | 09075V102 | $82.8M | 13.75% | 889,824 | SH |
| 5 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $49.7M | 8.25% | 1,333,333 | SH |
| 6 | CYTOKINETICS INC | CYTK | 23282W605 | $29.0M | 4.82% | 340,434 | SH |
| 7 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $21.3M | 3.53% | 1,512,659 | SH |
| 8 | SPERO THERAPEUTICS INC | SPRO | 84833T103 | $20.3M | 3.37% | 9,190,606 | SH |
| 9 | NKARTA INC | NKTX | 65487U108 | $8.9M | 1.48% | 3,150,732 | SH |
| 10 | FULCRUM THERAPEUTICS INC | FULC | 359616109 | $6.5M | 1.09% | 1,785,714 | SH |
| 11 | BICYCLE THERAPEUTICS PLC | BCYC | 088786108 | $6.5M | 1.08% | 1,529,561 | SH |
| 12 | CVRX INC | CVRX | 126638105 | $5.2M | 0.86% | 1,007,583 | SH |
| 13 | REGENXBIO INC | RGNX | 75901B107 | $3.3M | 0.54% | 271,456 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $602.2M | 13 | 0001999371-26-017873 |
| 2026-03-31 | 2026-05-14 | $599.2M | 13 | 0001999371-26-010742 |
| 2025-12-31 | 2026-02-12 | $799.0M | 15 | 0001999371-26-003198 |
LONDON WC1A 1DG